PATENT CLAIM ANALYSIS

Application Number: 16003210
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-02
Patent Classification: ["435", "006000"]

Abstract:
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Claim (Index 61):
A method of inhibiting JAK1 and/or JAK2 in a patient suffering from an autoimmune skin disease, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

Metadata:
- Claim Count in Document: 83.0
- Percentile: 94.0
- Lexical Diversity: 1.47826
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14943734', '14256311', '15164518', '14270915', '14256383']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5624009191320395
- 35 USC 102 Novelty (BERT): 0.5931329762813716
- Combined Prediction Score: 0.5654741248469728
- Mean Citation Score: 486.770494
- Max Citation Score: 498.19144000000006
- Similarity Product: 472.0042254795886

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test